Company Overview
GT Biopharma, Inc. operates as a clinical stage biopharmaceutical company dedicated to the development and commercialization of immuno-oncology products derived from its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. The company is currently advancing the development of GTB-3650, which has reached phase 1 status in its clinical progression. This entity functions within the Healthcare sector, specifically under the Biotechnology industry classification, a domain characterized by high research and development expenditures aimed at creating novel therapies for oncological conditions. The company's current scale is defined by a market capitalization of $12.90M and an operational footprint supported by 1 employee. These metrics indicate that GT Biopharma, Inc. is a micro-cap entity with minimal current revenue generation, reflecting its status as a pre-revenue development-stage organization that relies heavily on capital markets or other financing mechanisms to fund its clinical trials rather than operating cash flow.
Financial Health
The financial statements for the trailing twelve months reveal a Net Income of $-34,449,000, while Revenue and EBITDA are not available for the current reporting period. The significant gap between reported revenue figures (which are unavailable) and the substantial net loss highlights a cost structure dominated by research, development, and clinical trial expenses that far exceed any current sales revenue. The company reports Free Cash Flow of $-12,008,125, indicating a substantial outflow of capital required to sustain its clinical development activities and operational burn rate. Analysis of the profit margins shows a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, which collectively indicate that the company is not yet generating positive profitability from its operations or sales. In terms of liquidity and leverage, the company holds $6.81M in cash but has no reported debt, resulting in a Debt to Equity ratio that is not applicable due to the lack of debt figures. The absence of debt suggests a conservative balance sheet structure typical for early-stage biotechnology firms that prioritize preserving cash over taking on leverage. Short-term liquidity is supported by a Current Ratio of 3.50, which indicates that the company possesses ample current assets relative to its current liabilities to meet obligations over the next year. Return on Equity stands at -1377.4% and Return on Assets is -125.9%, metrics that reveal the company is currently utilizing its equity and asset base to generate significant losses rather than returns, a common characteristic of clinical-stage companies before product approval.
Valuation Assessment
The trailing twelve months P/E Ratio is not available, whereas the Forward P/E is reported as -0.04, implying that the market is pricing in expected future losses or that earnings are negative for the foreseeable future. The Price to Book ratio is 1.80, suggesting that the market values the company at 1.8 times its book value, which may reflect the potential value of its intellectual property and pipeline assets exceeding the value of its tangible net assets. The Price to Sales ratio and EV/EBITDA are both not available, meaning traditional sales-based or enterprise value multiples cannot be applied to value the company at this stage of development. The stock has exhibited significant volatility, trading between a 52-week low of $0.39 and a 52-week high of $3.85. Without a specific current price to calculate the exact percentage distance from the high, the range indicates a potential swing of over 90% from the low to the high over the past year. The Beta is 1.19, which signifies that the stock price is expected to be 19% more volatile than the broader market index. This elevated beta value suggests that the stock will likely experience larger price swings in both directions compared to the general market, increasing the risk profile for price-sensitive investors.
Growth & Income
Revenue Growth year-over-year and Earnings Growth year-over-year are both not available due to the lack of historical revenue data and the current loss-making status of the enterprise. Consequently, there is no historical earnings growth trajectory to compare against revenue growth, as the company has not yet achieved positive earnings to support a comparative analysis of efficiency. The company does not pay a dividend, evidenced by a Dividend Yield of not available and a Payout Ratio of 0.0%, which means all available cash and potential earnings are retained within the company to fund ongoing operations and development efforts. This reinvestment strategy is standard for clinical stage biopharmaceutical companies that must allocate capital toward advancing their pipeline through clinical trials rather than distributing income to shareholders. The overall growth and income profile for GT Biopharma, Inc. is defined by a complete absence of current dividends and historical growth rates, focusing entirely on capital preservation and pipeline advancement.